Peeling Back The Layers: Exploring Health Catalyst Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Health Catalyst (NASDAQ:HCAT) over the past quarter, with a range of price targets and opinions. The average 12-month price target is $12.75, slightly down from the previous $12.83. Recent actions include several analysts lowering their price targets, reflecting cautious sentiment.
May 21, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Health Catalyst (NASDAQ:HCAT) has received mixed analyst ratings over the past quarter, with an average 12-month price target of $12.75, down from $12.83. Several analysts have lowered their price targets recently, indicating a cautious outlook.
The mixed ratings and slight decrease in the average price target suggest a neutral short-term impact on HCAT's stock price. The recent downgrades by several analysts indicate a cautious sentiment, but the overall average price target remains relatively stable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100